Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alfredo Sánchez-Hernández"'
Autor:
Berta Hernandez, J. Coves, María Ángeles Sala, Ana Blasco, Ana Royuela, Joaquim Bosch-Barrera, A. Padilla, Roberto Serna-Blasco, María Sereno, Juana Oramas, María de Julián Campayo, Coralia Bueno, V. Calvo, Atocha Romero, José Balsalobre, F. Franco, Ana Laura Ortega, Milda Auglytė, Jose Miguel Sanchez, Mariano Provencio, Eloisa Jantus-Lewintre, X. Mielgo, Remedios Blanco, Carlos García-Girón, L.E. Chara, Miguel Angel Molina-Vila, Manuel Domine, Alfredo Sánchez-Hernández
Publikováno v:
European Journal of Cancer. 149:61-72
Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential
Autor:
José Vidal Martínez, Alfredo Sánchez Hernández, Javier Garde Noguera, Silvia Catot, Francisco Aparisi, Sonia Maciá, Gaspar Esquerdo Galiana, Oscar Juan, Ferran Losa Gaspá, Remei Blanco, Francisco Garcia-Pinon
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 17(4)
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-
Autor:
Oscar, Juan, Alfredo, Sánchez-Hernández, Sergio, Vázquez, Joaquín, Casal, José Luis, Firvida, Francisco, Aparisi, José, Muñoz, José, García-Sánchez, Regina, Gironés, Martín, Lázaro, Vicente, Giner
Publikováno v:
Anticancer research. 34(4)
To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC).Untreated patients with locally advanced inoperable stage IIIA/IIIB NS